Literature DB >> 24641546

In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.

A Kuo1, B D Wyse, W Meutermans, M T Smith.   

Abstract

BACKGROUND AND
PURPOSE: For patients experiencing inadequate analgesia and intolerable opioid-related side effects on one strong opioid analgesic, pain relief with acceptable tolerability is often achieved by rotation to a second strong opioid. These observations suggest subtle pharmacodynamic differences between opioids in vivo. This study in rats was designed to assess differences between opioids in their in vivo profiles. EXPERIMENTAL APPROACH: Male Sprague Dawley rats were given single i.c.v. bolus doses of morphine, morphine-6-glucuronide (M6G), fentanyl, oxycodone, buprenorphine, DPDPE ([D-penicillamine(2,5) ]-enkephalin) or U69,593. Antinociception, constipation and respiratory depression were assessed using the warm water tail-flick test, the castor oil-induced diarrhoea test and whole body plethysmography respectively. KEY
RESULTS: These opioid agonists produced dose-dependent antinociception, constipation and respiratory depression. For antinociception, morphine, fentanyl and oxycodone were full agonists, buprenorphine and M6G were partial agonists, whereas DPDPE and U69,593 had low potency. For constipation, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, morphine produced a bell-shaped dose-response curve, whereas DPDPE and U69,593 were inactive. For respiratory depression, morphine, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, whereas DPDPE and U69,593 were inactive. The respiratory depressant effects of fentanyl and oxycodone were of short duration, whereas morphine, M6G and buprenorphine evoked prolonged respiratory depression. CONCLUSION AND IMPLICATIONS: For the seven opioids we assessed, no two had the same profile for evoking antinociception, constipation and respiratory depression, suggesting that these effects are differentially regulated. Our findings may explain the clinical success of 'opioid rotation'. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  antinociception; buprenorphine; constipation; fentanyl; intracerebroventricular; morphine; morphine-6-glucuronide (M6G); oxycodone; rat; respiratory depression

Mesh:

Substances:

Year:  2014        PMID: 24641546      PMCID: PMC4292966          DOI: 10.1111/bph.12696

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  70 in total

1.  G-protein-coupled receptor heterodimerization modulates receptor function.

Authors:  B A Jordan; L A Devi
Journal:  Nature       Date:  1999-06-17       Impact factor: 49.962

2.  In vivo dynamics and distribution of intracerebroventricularly administered gadodiamide, visualized by magnetic resonance imaging.

Authors:  J D Bui; D R Nammari; D L Buckley; B A Inglis; X S Silver; T H Mareci; M I Phillips
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

Review 3.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

4.  Intracerebroventricular and intrathecal injectate spread in rats.

Authors:  T J Luger; A Kathrein; M Rieger; I H Lorenz
Journal:  Eur J Anaesthesiol       Date:  2005-03       Impact factor: 4.330

5.  The cerebral ventricles of the rat.

Authors:  I M Levinger
Journal:  J Anat       Date:  1971-04       Impact factor: 2.610

6.  Bremazocine: a potent, long-acting opiate kappa-agonist.

Authors:  D Römer; H Büscher; R C Hill; R Maurer; T J Petcher; H B Welle; H C Bakel; A M Akkerman
Journal:  Life Sci       Date:  1980-09-15       Impact factor: 5.037

7.  Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.

Authors:  K O Lee; H Akil; J H Woods; J R Traynor
Journal:  Eur J Pharmacol       Date:  1999-08-13       Impact factor: 4.432

8.  A preclinical comparison between different opioids: antinociceptive versus adverse effects.

Authors:  Theo F Meert; Hilde A Vermeirsch
Journal:  Pharmacol Biochem Behav       Date:  2005-01-07       Impact factor: 3.533

9.  Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat.

Authors:  Susanna Fürst; Pal Riba; Tamas Friedmann; Julia Tímar; Mahmoud Al-Khrasani; Ilona Obara; Wioletta Makuch; Mariana Spetea; Johannes Schütz; Ryszard Przewlocki; Barbara Przewlocka; Helmut Schmidhammer
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

10.  Respiratory depression produced by activation of GABA receptors in hindbrain of cat.

Authors:  K A Yamada; P Hamosh; R A Gillis
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-11
View more
  18 in total

Review 1.  A Biased View of μ-Opioid Receptors?

Authors:  Alexandra E Conibear; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

2.  A "tail" of opioid receptor variants.

Authors:  Stephanie Puig; Howard B Gutstein
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

Review 3.  Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl.

Authors:  Eugene A Kiyatkin
Journal:  Neuropharmacology       Date:  2019-02-05       Impact factor: 5.250

4.  Identification of the First Marine-Derived Opioid Receptor "Balanced" Agonist with a Signaling Profile That Resembles the Endorphins.

Authors:  Tyler A Johnson; Laura Milan-Lobo; Tao Che; Madeline Ferwerda; Eptisam Lambu; Nicole L McIntosh; Fei Li; Li He; Nicholas Lorig-Roach; Phillip Crews; Jennifer L Whistler
Journal:  ACS Chem Neurosci       Date:  2016-11-22       Impact factor: 4.418

5.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

6.  Pain And Opioid Systems, Implications In The Opioid Epidemic.

Authors:  Nicolas Massaly; Jose A Morón
Journal:  Curr Opin Behav Sci       Date:  2018-10-30

Review 7.  Targeting voltage-gated calcium channels in neurological and psychiatric diseases.

Authors:  Gerald W Zamponi
Journal:  Nat Rev Drug Discov       Date:  2015-11-06       Impact factor: 84.694

8.  Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Authors:  Sarah L Withey; Carol A Paronis; Jack Bergman
Journal:  J Pain       Date:  2018-03-02       Impact factor: 5.820

9.  No antinociceptive synergy between morphine and delta-9-tetrahydrocannabinol in male and female rats with persistent inflammatory pain.

Authors:  Stevie C Britch; Rebecca M Craft
Journal:  Behav Pharmacol       Date:  2021-12-01       Impact factor: 2.293

10.  The use of hypercapnic conditions to assess opioid-induced respiratory depression in rats.

Authors:  Morgan L Crowley; Luis F Restrepo; Lea R Gamez-Jimenez; Avi Patel; Tobias Braun; Victoria L C Pallares; Nicholas P Ho; Morgan E Reeves; Christopher R McCurdy; Lance R McMahon; Takato Hiranita
Journal:  J Pharmacol Toxicol Methods       Date:  2021-07-07       Impact factor: 2.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.